Value
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 9.1 |
| P/S | 9.2 |
| EV/EBITDA | 2.2 |
| Fwd P/E | 9.1 |
| PEG | 6.1 |
| Analyst target | 4.0 |
- ▸Forward P/E: 11.1x
- ▸PEG: 1.22
SOLV · Why this verdict
Why Solventum (SOLV) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.8/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The stock trades at a forward price-to-earnings ratio of roughly 10.9 times with a price-to-earnings growth ratio of 1.22, and the bull case cites a 37% margin of safety relative to estimated intrinsic value. Valuation breakdown | The valuation discount narrows over 12 months as the market re-rates the stock closer to a 13-15x forward multiple, implying at least 20% price appreciation from the current $76.90. | →Stable |
| CounterA weak Piotroski financial strength score of 3 out of 9 and free cash flow that represents only 26% of reported net income suggest earnings quality issues that may justify a sustained discount. | ||
Solventum has beaten analyst earnings estimates in all four of the most recent quarters, with an average positive surprise of 8.8% and the most recent beat reaching 9.3% above the consensus estimate of $1.35. Earnings | Earnings beats continue in at least 3 of the next 4 quarters, sustaining or expanding the average surprise above 5% per quarter. | →Stable |
| CounterThe beat streak has been narrowing (9.3% most recent vs. 16.3% a year prior), and declining revenue of about -3% year-over-year could compress margins and end the streak. | ||
Solventum's return on equity stands at 35%, which the quality analysis notes as excellent and superior relative to industry peers, providing a meaningful profitability edge in the medical instruments and supplies space. Quality breakdown | Return on equity remains above 25% over the next four quarters, maintaining its peer-superior ranking in profitability assessments. | →Stable |
| CounterHigh leverage (debt-to-equity of 1.1 penalized in the bear case) artificially inflates return on equity; if debt is refinanced at higher rates, the underlying return on assets of only 1.8 reveals far weaker core business economics. | ||
Price momentum is clearly negative, with an options market put-to-call ratio of 1.51, implied volatility of 64%, and falling on-balance volume indicating that institutional sellers currently outweigh buyers. Key risks | Momentum improves: on-balance volume trends upward and the put-to-call ratio falls below 1.0 within six months as selling pressure exhausts itself. | →Stable |
| CounterMomentum weakness may persist for many quarters in a range-bound stock that has already reached the analyst price target, leaving the reward-to-risk ratio at only 0.9:1. | ||
The stock trades at a forward price-to-earnings ratio of roughly 10.9 times with a price-to-earnings growth ratio of 1.22, and the bull case cites a 37% margin of safety relative to estimated intrinsic value.
→StableValuation breakdown
- Expectation
- The valuation discount narrows over 12 months as the market re-rates the stock closer to a 13-15x forward multiple, implying at least 20% price appreciation from the current $76.90.
CounterA weak Piotroski financial strength score of 3 out of 9 and free cash flow that represents only 26% of reported net income suggest earnings quality issues that may justify a sustained discount.
Solventum has beaten analyst earnings estimates in all four of the most recent quarters, with an average positive surprise of 8.8% and the most recent beat reaching 9.3% above the consensus estimate of $1.35.
→StableEarnings
- Expectation
- Earnings beats continue in at least 3 of the next 4 quarters, sustaining or expanding the average surprise above 5% per quarter.
CounterThe beat streak has been narrowing (9.3% most recent vs. 16.3% a year prior), and declining revenue of about -3% year-over-year could compress margins and end the streak.
Solventum's return on equity stands at 35%, which the quality analysis notes as excellent and superior relative to industry peers, providing a meaningful profitability edge in the medical instruments and supplies space.
→StableQuality breakdown
- Expectation
- Return on equity remains above 25% over the next four quarters, maintaining its peer-superior ranking in profitability assessments.
CounterHigh leverage (debt-to-equity of 1.1 penalized in the bear case) artificially inflates return on equity; if debt is refinanced at higher rates, the underlying return on assets of only 1.8 reveals far weaker core business economics.
Price momentum is clearly negative, with an options market put-to-call ratio of 1.51, implied volatility of 64%, and falling on-balance volume indicating that institutional sellers currently outweigh buyers.
→StableKey risks
- Expectation
- Momentum improves: on-balance volume trends upward and the put-to-call ratio falls below 1.0 within six months as selling pressure exhausts itself.
CounterMomentum weakness may persist for many quarters in a range-bound stock that has already reached the analyst price target, leaving the reward-to-risk ratio at only 0.9:1.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Solventum has delivered four consecutive quarterly earnings beats with an average surprise of 8.8%, demonstrating reliable profit execution in medical instruments, though weak price momentum and a poor free-cash-flow ratio relative to net income limit near-term entry appeal.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
5.0/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 10.0 |
| ROA | 1.8 |
| Gross margin | 6.7 |
| Op margin | 2.2 |
| Net margin | 8.7 |
| Current ratio | 4.2 |
| FCF quality | 2.1 |
| Moat | 5.8 |
| Piotroski F | 3.3 |
- ▸Excellent ROE: 35%
- ▸Strong margins: 17%
- ▸Earnings quality RED FLAG: 26% FCF/NI
- ▸Weak Piotroski F-Score: 3/9
Growth
0.9/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 1.8 |
| EPS growth | 0.0 |
- ▸Declining revenue: -3%
Momentum
4.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 3.0 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 2.3 |
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.2 |
| Price target | 5.7 |
| erm sentiment | 5.7 |
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
4.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 8.5 |
| quality rank | 9.0 |
| growth rank | 0.7 |
- ▸Attractive P/E vs peers
- ▸Superior ROE vs peers
Technical
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 4.7 |
| support resistance | 5.0 |
| 52w position | 7.7 |
Risk (lower is worse)
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.2 |
| days to cover | 8.4 |
| volatility | 5.3 |
| put call | 7.8 |
| implied vol | 4.1 |
| beta | 8.7 |
| debt equity | 4.9 |
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 6.9 |
- ▸Perfect beat streak: 4Q
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (5)
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:34d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:4.2<4.5
- ASYMMETRY:-1.3=NEGATIVE
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
-1.30
Upside
-8.7%
Downside
6.7%
Sizing output
AVOID
SetupRange Bound — RSI 47 mid-range, Bollinger mid-band
EdgeNo clear edge — No clear edge identified
SuitabilityModerate — Balanced profile
Investment implication
The F-path SELL output reflects an overall score of 4.3 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Risk (lower is worse) at 6.8) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( MOMENTUM:4.2<4.5, ASYMMETRY:-1.3=NEGATIVE) reinforce the read. Current asymmetry R:R is -1.30 — supplementary context, not the trigger for this path.
The strongest dimensions are Risk (lower is worse) at 6.8, Catalyst at 6.7, and Value at 6.6; the weakest are Growth at 0.9, Momentum at 4.2, and Peer rank at 4.5. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of -1.30 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Consistent Earnings Beat Streak
Trip ifEarnings surprise falls below 0% in at least 2 of the next 4 quarters, ending the beat streak.
- P2Valuation Margin Of Safety
Trip ifForward price-to-earnings ratio rises above 14x without a corresponding improvement in revenue growth, eliminating the margin of safety.
- P3Return On Equity Peer Advantage
Trip ifReturn on equity drops below 20% for 2 consecutive quarters as leverage costs rise.
- P4Momentum Headwind Risk
Trip ifPut-to-call ratio rises above 2.0 or implied volatility exceeds 80%, signaling accelerating bearish positioning.